Wang, Bushi
Boehringer Ingelheim (Germany) · Boehringer Ingelheim (United States)
3 papers on CoChatORCID 0000-0001-8916-9416
Most cited papers
- Verified
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine
Atrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis Mechanisms
Cited by 1,552
- Verified
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Isla, D., et al. (2015) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 433
- Verified
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations
Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 362
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free